Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
BAL PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BAL PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
BAL PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 134 | 316 | - | |
Low | Rs | 63 | 228 | - | |
Sales per share (Unadj.) | Rs | 193.9 | 94.0 | - | |
Earnings per share (Unadj.) | Rs | 1.7 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | 7.5 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
Avg Dividend yield | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 40.7 | 73.8 | - | |
Shares outstanding (eoy) | m | 15.69 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.5 | 2.9 | 17.6% | |
Avg P/E ratio | x | 59.2 | -11.5 | -515.2% | |
P/CF ratio (eoy) | x | 13.2 | -13.9 | -95.2% | |
Price / Book Value ratio | x | 2.4 | 3.7 | 65.9% | |
Dividend payout | % | 59.9 | 0 | - | |
Avg Mkt Cap | Rs m | 1,549 | 45,919 | 3.4% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 553 | 2,882 | 19.2% | |
Avg. sales/employee | Rs Th | 0 | 3,696.8 | - | |
Avg. wages/employee | Rs Th | 0 | 671.3 | - | |
Avg. net profit/employee | Rs Th | 0 | -931.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,042 | 15,870 | 19.2% | |
Other income | Rs m | 9 | 111 | 8.5% | |
Total revenues | Rs m | 3,052 | 15,982 | 19.1% | |
Gross profit | Rs m | 253 | -2,750 | -9.2% | |
Depreciation | Rs m | 91 | 685 | 13.3% | |
Interest | Rs m | 123 | 430 | 28.6% | |
Profit before tax | Rs m | 47 | -3,754 | -1.3% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 21 | 235 | 9.1% | |
Profit after tax | Rs m | 26 | -3,999 | -0.7% | |
Gross profit margin | % | 8.3 | -17.3 | -47.9% | |
Effective tax rate | % | 44.8 | -6.2 | -717.6% | |
Net profit margin | % | 0.9 | -25.2 | -3.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,282 | 11,624 | 19.6% | |
Current liabilities | Rs m | 2,093 | 6,540 | 32.0% | |
Net working cap to sales | % | 6.2 | 32.0 | 19.3% | |
Current ratio | x | 1.1 | 1.8 | 61.3% | |
Inventory Days | Days | 8 | 111 | 6.9% | |
Debtors Days | Days | 1,128 | 124 | 909.7% | |
Net fixed assets | Rs m | 829 | 6,775 | 12.2% | |
Share capital | Rs m | 157 | 74 | 212.9% | |
Net worth | Rs m | 638 | 12,457 | 5.1% | |
Long term debt | Rs m | 305 | 4,377 | 7.0% | |
Total assets | Rs m | 3,110 | 23,531 | 13.2% | |
Interest coverage | x | 1.4 | -7.7 | -17.9% | |
Debt to equity ratio | x | 0.5 | 0.4 | 136.2% | |
Sales to assets ratio | x | 1.0 | 0.7 | 145.0% | |
Return on assets | % | 4.8 | -15.2 | -31.7% | |
Return on equity | % | 4.1 | -32.1 | -12.8% | |
Return on capital | % | 18.1 | -19.8 | -91.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -18 | 1,355 | -1.4% | |
From Investments | Rs m | -222 | -416 | 53.3% | |
From Financial Activity | Rs m | 244 | 3,973 | 6.1% | |
Net Cashflow | Rs m | 4 | 4,912 | 0.1% |
Compare BAL PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare BAL PHARMA With: SHILPA MEDICARE MOREPEN LABS HESTER BIOSCIENCES PIRAMAL PHARMA MARKSANS PHARMA.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.